Source comparison
Clinical Application: EPP Treatment vs Off-Label Use
Scenesse's FDA approval is narrow and specific: it treats erythropoietic protoporphyria by increasing eumelanin density in the skin, which absorbs visible light (especially blue wavelengths around 400–410nm) that triggers phototoxic reactions in EPP patients.
This comparison does not assign a generated winner or score.
- Scenesse's FDA approval is narrow and specific: it treats erythropoietic protoporphyria by increasing eumelanin density in the skin, which absorbs visible light (especially blue wavelengths around 400–410nm) that triggers phototoxic reactions in EPP patients. Clinical trials demonstrated that afamelanotide implants increased pain-free sun exposure time by 69.4 minutes compared to placebo over a 9-month period—a clinically meaningful improvement for patients whose baseline tolerance is often under 30 minutes. The treatment doesn't cure EPP; it mitigates symptom severity by raising the threshold for phototoxic damage.
- Melanotan-1 has no approved clinical indication. It's used off-label (and often illegally) for cosmetic tanning, theoretically for photoprotection in individuals with fair skin, and experimentally for erectile dysfunction research due to melanocortin receptor effects on vascular tissue. None of these uses have undergone Phase III trials. The cosmetic tanning application is the most common—users inject 0.5–1mg daily during a 'loading phase' of 10–14 days to build melanin density, then reduce to maintenance doses of 0.5mg twice weekly. This protocol is anecdotal, not evidence-based.
- The honest answer: using Melanotan-1 for tanning is using a pharmaceutical analog without pharmaceutical oversight. It works—MC1R activation is a well-characterized pathway—but you're bypassing the safety infrastructure that exists for a reason. Scenesse's clinical data includes adverse event tracking across 1,500+ patient-years of exposure; Melanotan-1 has no equivalent dataset. If you experience nausea, flushing, or unexpected hyperpigmentation with research peptides, there's no pharmacovigilance system documenting whether it's a common reaction or a contamination issue.